Patents Assigned to Hadasit
  • Isotopically labeled deoxy-glucose and derivatives thereof, compositions comprising them and uses thereof
    Patent number: 10814018
    Abstract: The present invention provides isotopically labeled deoxy-glucose and derivatives thereof, methods of their preparation, ration, kits comprising them and uses thereof for spin hyperpolarized magnetic resonance imaging, utilized in the quantitative and qualitative diagnosis of states, conditions, diseases, or disorders in the body of a subject.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: October 27, 2020
    Assignee: HADASIT MEDICAL RESEARCH SERVICE & DEVELOPMENT LTD.
    Inventors: Moshe Gomori, Hyla Allouche-Arnon, Rachel Katz-Brull
  • Radiolabeled erlotinib analogs and uses thereof
    Patent number: 10710968
    Abstract: Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distribution and/or mutational status of deregulated EGFR, and/or in radiotherapy, are also disclosed.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: July 14, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Eyal Yosef Mishani, Ofer Shamni, Galith Rachel Abourbeh-Gofrit
  • Devices and methods for percutaneous endoscopic gastrostomy and other ostomy procedures
    Patent number: 10695270
    Abstract: Ostomy tubes, particularly gastrostomy tubes, with improved retention means are provided. More specifically, retention structures, such as bolsters, for gastrostomy tubes are provided, configured to removably assemble to one end of a gastrostomy tube to facilitate replacement and removal of the tube. The retention structures provided herein may comprise one or more removably assembled retention elements. Further provided are gastrostomy tubes comprising such retention structures, and methods for percutaneous endoscopic gastrostomy utilizing same.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: June 30, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Ishay Benuri-Silbiger
  • FORMATION OF STABLE CARTILAGE
    Publication number: 20200171215
    Abstract: Methods are provided for promoting cartilage growth and/or repair. The methods include, administering locally to a site in a subject in need thereof, bone marrow stromal cells attached to fibrin microbeads comprising crosslinked hyaluronic acid and thereby producing stable cartilage locally at the site in the subject.
    Type: Application
    Filed: May 31, 2018
    Publication date: June 4, 2020
    Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Pamela Gehron Robey, Sergei Kuznetsov, Raphael Gorodetsky, Astar Hailu-Lazmi, Mitchell Shirvan, Joseph Featherall
  • DETECTING TISSUE-SPECIFIC DNA
    Publication number: 20200165671
    Abstract: A method of determining the methylation status of at least one methylation site of a double-stranded DNA molecule is disclosed. The method comprises analyzing the methylation status of both the forward strand and the reverse strand of the DNA molecule.
    Type: Application
    Filed: July 13, 2018
    Publication date: May 28, 2020
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Yuval DOR, Ruth SHEMER, Benjamin GLASER, Judith MAGENHEIM
  • Extracts of edible fungi enriched in vitamin D and compostions thereof and their use in the treatment of immune-related disorders
    Patent number: 10617697
    Abstract: A vitamin D2-enriched biomass of an edible fungus, extracts and compositions thereof are provided, for use in delaying onset of, treating, ameliorating or protecting from an immune-related or inflammatory related disease, disorder or condition, wherein the level of vitamin D2 in said biomass is at least 80 IU/gr.
    Type: Grant
    Filed: January 17, 2016
    Date of Patent: April 14, 2020
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD
    Inventors: Dan Levanon, Yaron Ilan, Ofer Danai
  • PAR1 and PAR2 c-tail peptides and peptide mimetics
    Patent number: 10611798
    Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: April 7, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rachel Bar-Shavit
  • Methods for treating or reducing liver diseases by administering oral composition comprising TNF receptor fusion proteins
    Patent number: 10611821
    Abstract: This application describes a method of delivering a TNF antagonist molecule, in a biologically active form, to a subject in need thereof, the method comprising, orally or mucosally administering to the subject a therapeutically effective amount of a TNF antagonist molecule. This application further describes a method of treating, preventing or reducing liver diseases, the method comprising, administering to the subject a therapeutically effective amount of a TNF antagonist molecule.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: April 7, 2020
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventor: Yaron Ilan
  • INTRACRANIAL VOLUME ADAPTOR FOR CEREBRAL BLOOD FLOW
    Publication number: 20200061355
    Abstract: A method for influencing cerebral perfusion in a patient by modifying a volume of a volume adaptor introduced into a cerebral ventricle of the patient, the method comprising identifying a timing of a cerebral blood inflow and/or outflow in a cardiac activity of the patient, modifying a volume of the volume adaptor in synchronization to the identified timing of the cerebral blood flow, to an amount sufficient to modify an intracranial pressure in the cerebral ventricle, such that a flow of the cerebral blood flow is enhanced. In some exemplary embodiments of the invention, the inflation duration of the volume adapter is short relative to the cardiac cycle.
    Type: Application
    Filed: November 16, 2017
    Publication date: February 27, 2020
    Applicants: Ramot at Tel-Aviv University Ltd., Tel HaShomer Medical Research Infrastructure and Services Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Ofer BARNEA, Omer DORON
  • PHOTORECEPTOR CELLS FOR THE TREATMENT OF RETINAL DISEASES
    Publication number: 20200032204
    Abstract: A method of generating photoreceptor cells is disclosed. Cell populations comprising photoreceptor cells and uses thereof are also disclosed.
    Type: Application
    Filed: February 8, 2018
    Publication date: January 30, 2020
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin E. Reubinoff, Masha Gorshtein, Hanita Khaner, Alex Obolensky, Eyal Banin
  • Formulations of 6-mercaptopurine
    Patent number: 10525009
    Abstract: The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 7, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Itzhak E. Lerner, Moshe Flashner-Barak, Erwin v Achthoven, Hans Keegstra, Ruud Smit
  • INHIBITORS OF NEUROLIGIN 4-NEUREXIN 1-BETA PROTEIN-PROTEIN INTERACTION FOR TREATMENT OF LIVER DISORDERS
    Publication number: 20190389948
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Application
    Filed: May 9, 2019
    Publication date: December 26, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat SAFADI
  • Alginate compositions and uses thereof
    Patent number: 10500226
    Abstract: Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than ?25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10?8 cm2/second, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease; liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: December 10, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
    Inventors: Smadar Cohen, Yaron Ilan, Eyal Shteyer, Ami Ben-Ya'Acov
  • Sustained release delivery systems for the prevention and treatment of head and neck cancers
    Patent number: 10485792
    Abstract: The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: November 26, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Michael Friedman, Rakefet Czernimski, Silvio Gutkind, Doron Steinberg, Irith Gati, Zakhar Nudelman
  • Use of full-length amelogenin for promoting nerve growth or regeneration
    Patent number: 10478476
    Abstract: A method of promoting nerve growth or regeneration in a subject in need thereof, wherein the subject is not afflicted with a substantial connective tissue damage, is provided. The method comprises administering to the subject a therapeutically effective amount of full-length amelogenin, thereby promoting nerve growth or regeneration in the subject.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: November 19, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Amir Haze, Anat Blumenfeld, Dan Deutsch
  • Anti-LPS enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
    Patent number: 10464998
    Abstract: This invention relates to methods and compositions for treating fibrosis, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. In particular, the invention relates to methods and compositions for the treatment of liver fibrosis and/or lung fibrosis. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: November 5, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED
    Inventors: Yaron Ilan, Meir Mizrahi
  • CELL COMPOSITIONS AND METHODS FOR CANCER THERAPY
    Publication number: 20190330303
    Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Application
    Filed: May 20, 2019
    Publication date: October 31, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD
    Inventors: Abraham RUTENBERG, Ronny UZANA, Michal LOTEM, Arthur MACHLENKIN, Galit EISENBERG, Tamar PERETZ-YABLONSKY, Shoshana FRANKENBURG, Roni ENGELSTEIN
  • Nitroxide radicals for the treatment of diseases of the respiratory tract
    Patent number: 10441568
    Abstract: Cyclic nitroxide compounds including, but not limited to, compounds having the general formula I: wherein the dashed line and R1-R8 are as defined herein, are disclosed herein for use in treating diseases and disorders of the respiratory tract and/or respiratory tract remodeling.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: October 15, 2019
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Sara Goldstein, Amram Samuni, Neville Berkman
  • Type III deiodinase inhibitors and uses thereof
    Patent number: 10435365
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: October 8, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
    Inventors: Bernard Lerer, Mugesh Govindasamy, Tzuri Lifschytz
  • METHOD OF OBTAINING TERMINALLY DIFFERENTIATED NEURONAL LINEAGES AND USES THEREOF
    Publication number: 20190264172
    Abstract: Provided is a method of inducing transdifferentiation of mesenchymal stem cells (MSC), the method including (a) culturing MSC in a first culture medium including a growth factor selected for allowing formation of neuralized MSC (NMSC); (b) allowing the NMSC to proliferate for a sufficient time during which said culture medium is renewed at least once; and (c) culturing the NMSC of (b) in a second culture media including cerebrospinal fluid (CSF) for a time sufficient for the NMSC to differentiate into a population of cells including terminally differentiated neurons, astrocytes and oligodendrocytes. Also provided by the present invention is the use of MSC or NMSC for providing a composition including said population and to kits including MSC or NMSC and instructions for use of same.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Applicant: Hadasit Medical Research Services & Development Limited
    Inventors: Dimitrios KARUSSIS, Ibrahim KASSIS